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1. Introduction
Acute leukemias are cancers of the hematopoietic system that involve, in the majority of cases,
a malignant transformation of myeloid and lymphoid progenitor cells [1]. Acute leukemias
represent the most common type of childhood cancer [2,3]. Acute lymphoblastic leukemia
(ALL) has a frequency of five times greater than that of acute myeloblastic leukemia (AML)
and is the most common cancer in children, representing 25% to 35% of all childhood cancers
[3,4]. The incidence of ALL varies significantly among developed and developing countries.
With a reported annual incidence of 20-45 cases per million children, the highest incidence
rates are recorded in the Hispanic population in California, Texas and Florida and in Costa
Rica and the City of Mexico [4-7]. Despite advances in therapy and improvements in survival,
acute leukemia represents one of the main causes of morbidity and mortality in children. The
etiology of this disease remains unknown. Only Down syndrome and ionizing radiation have
been recognized as risk factors for the development of childhood acute leukemia [8]. However,
the risk attributable to these factors is very small. Epidemiological studies exploring different
environmental exposures along with advances in cytogenetics and immunophenotyping have
identified different subgroups of the disease that must be considered separately. Such is the
case of infantile leukemia. Although it is a rare disease in this group, the molecular character‐
istics and survival are different in infants than in older children, suggesting that the etiology
is distinct and most likely involves prenatal factors. The purpose of this chapter is to introduce
the reader to a systematic review of the current literature on reported risk factors for childhood
acute leukemia (AL). This review reports what is currently known about acute leukemia in
infants and future directions.
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2. Descriptive epidemiology
Leukemia in infants (<1 year) is an extremely rare disease, and few studies exist that explore
the incidence of leukemia in this age group. Parkin et al., reporting incidence rates for this age
group in different regions of the world, determined that Mexico recorded the highest incidence
rate in children <1 year for the study period, exceeding the rates of the United States, some
countries in Latin America, Europe, Asia and Oceania [5]. However, United States, Great
Britain, and Australia have some of the highest incidence rates for infantile ALL, with
approximately 20-40 cases per million children, whereas countries like Brazil and Cuba have
reported rates of approximately 8-12 cases per million children. The Hispanic population of
infants in Los Angeles, Japan and Australia has been reported to have the highest AML
incidence rates of approximately 10-12 cases per million children. As with ALL, Brazil and
Cuba have some of the lowest incidence rates, with approximately 3-5 cases per million
children [6].
Descriptive epidemiological studies conducted in Mexico City on acute leukemia and child‐
hood cancer have consistently identified a significant incidence for AL in the infant population.
In the 1980-1992 study period, in newborns population ALL occupied the third place as the
main type of cancer and the second place in the infant population and after 2 years of age, a
very important peak in AL development is observed [9]. For the period 1996-2002, the
incidence of AL in infants was 37.5 per 106 children [10,11], and between 1996 and 2006 another
study reported an incidence of 33.0 ALL cases per 106 children < 1 year of age [12]. The most
recent survey of childhood AL in 2006-2007 in Mexico City reported an incidence rate of ALL
and AML of 24.3 and 4.1 per 106 infants, respectively [7].
Epidemiological studies in infants are rare. However, there is a predominance of females in
infants with ALL, whereas in children older than 1 year, male are more frequently diagnosed
[13]. Because of the young age of presentation of infantile leukemia, studies are focused
specifically on pre-conception exposures during pregnancy as potentially relevant exposures
that occur in utero or shortly before pregnancy. That is, the window of study for the disease in
this cohort is very short – approximately 9 months. Therefore, the study of this group can
provide essential information not only for this group but also for the development of childhood
AL [14,15]. The epidemiological studies have evaluated maternal exposure during pregnancy
to different risk factors that could be associated with the development of leukemia in infants.
These studies are presented in table 1 and include the publication of epidemiological studies
in the last 12 years in the infant population and its association with AL. Although the studies
are interesting and provide important information, some studies have failed to find significant
associations because they have some methodological limitations, such as sample size (small
number of exposed individuals among subgroups) or incomplete and biased exposure
assessment (not validated). In some cases they have a low response rates between cases and
controls. It is important to consider these aspects for future association studies. Despite these
limitations, these studies provide an important contribution to the limited amount of existing
studies linking infants with AL and risk factors.
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Variables studied Study design Cases analyzed OR (95% CI) Conclusions Author and year
Maternal exposure to
household
chemicals
Case-control 264 ALL Petroleum products Any Gestational exposure to petrole‐
um products was associated with
infant leukemia, particularly AML
and MLL-.
Slater et al.,
2011[23]172 AML ALL OR 1.56 (0.90-2.70); AML OR 2.33
(1.30-4.18); MLL+ OR 1.38 (0.77-2.48)
7 Other Month before pregnancy
 ALL OR 1.31 (0.71-2.41); AML OR 1.42
(0.71-2.83); MLL+ OR 1.14 (0.58-2.21)
 During pregnancy
 ALL OR 1.60 (0.90-2.83); AML OR 2.54
(1.40-4.62); MLL- 2.69 (1.47-4.93)
Analgesic use
during pregnancy
Case-control 262 ALL Before knowledge pregnancy Any use Analgesic use during pregnancy
was not significantly associated
with the risk of infant leukemia.
Ognjanovic et al.,
2011[24]172 AML Aspirin
 ALL OR 1.03 (0.58-1.85)
 AML OR 0.55 (0.24-1.26)
 Non-aspirin non-steroidal anti-inflam‐
matory drugs (NSAID)
 ALL OR 1.15 (0.80-1.67)
 AML OR 0.60 (0.37-0.97)
 Acetaminophen
 ALL OR 1.16 (0.80-1.68)
 AML OR 0.66 (0.43-1.01)
 After knowledge pregnancy Any use
 Aspirin
 ALL OR 1.21 (0.48-3.05)
 AML OR 0.96 (0.32-2.92)
 NSAID
 ALL OR 1.33 (0.75-2.37)
 AML OR 0.81 (0.36-1.83)
 Acetaminophen
 ALL OR 1.03 (0.70-1.53)
 AML OR 0.79 (0.50-1.24)
Maternal prenatal cig‐
arette, alcohol and il‐
licit drug use
Case-control 264 ALL During pregnancy Cigarette smoking was not asso‐
ciated with childhood leukemia;
alcohol and illicit drug use were
not consistent with prior reports.
Slater et al.,
2011[25]172 AML Cigarette use
7 Other OR 0.80 (0.52-1.24)
 ALL OR 0.87 (0.54-1.40)
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Variables studied Study design Cases analyzed OR (95% CI) Conclusions Author and year
 AML OR 0.74 (0.40-1.35)
 Alcohol use
 OR 0.64 (0.43-0.94)
 ALL OR 0.64 (0.43-0.94)
 Illicit drug use
 OR 0.69 (0.40-1.18)
 ALL OR 0.84 (0.47-1.51)
 AML OR 0.52 (0.23-1.16)
Maternal vitamin and
iron supplementation
Case-control 264 ALL Prenatal The authors did not observe a
prenatal vitamin-infant leukemia
association.
Linabery et al.,
2010 [26]172 AML Vitamins
 OR 0.79 (0.44-1.42)
 ALL OR 0.63 (0.34-1.18)
 AML OR 1.20 (0.53-2.75)
 Iron supplements
 OR 1.07 (0.75-1.52)
 ALL OR 1.22 (0.82-1.80)
 AML OR 0.82 (0.51-1.33)
 Periconceptional
 Vitamins
 OR 0.89 (0.64-1.24)
 ALL OR 0.77 (0.54-1.11)
 AML OR 1.05 (0.68-1.61)
 Iron supplements
 OR 1.23 (0.63-2.38)
 ALL OR 1.30 (0.62-2.72)
Continued…   AML OR 0.77 (0.46-1.27)   
During pregnancy
Vitamins
OR 0.78 (0.48-1.28)
ALL OR 0.66 (0.39-1.11)
AML OR 1.05 (0.55-2.04)
Iron supplements
OR 1.06 (0.74-1.53)
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Variables studied Study design Cases analyzed OR (95% CI) Conclusions Author and year
ALL OR 1.22 (0.81-1.84)
AML OR 0.77 (0.46-1.27)
Congenital
abnormalities
Case-control 264 ALL Congenital abnormality (CA) The authors did not find evi‐
dence for a link between CAs
and infant leukemia
Johnson et al.,
2010 [27]172 AML OR 1.2 (0.8-1.9)
7 Other Birthmarks
 OR 1.3 (0.7-2.4)
 Urogenital abnormalities
 OR 0.7 (0.2-2.0)
 Other CA
 OR 1.4 (0.7-2.8)
Parental infertility and
infertility
treatment
Case-control 264ALL Women not trying to conceive There were no positive associa‐
tions between parental infertility
or infertility treatment and infant
leukemia.
Puumala et al.,
2010 [28]172 AML OR 1.62 (1.01-2.59)
 ALL OR 2.50 (1.36-4.61)
 AML OR 1.17 (0.61-2.22)
 Women with ≥1 year of trying
 OR 0.99 (0.47-2.07)
 ALL OR 2.01 (0.85-4.78)
 AML 0.35 (0.09-1.27)
Dipyrone Case-control 132 Acute leukemia N-Acetyltransferase 2 (NAT2) dipyrone
during pregnancy
NAT2 slow-acetylation profiles
associated with infant leukemia
&dipyrone
Zanrosso et al.,
2010 [29]
OR 5.19 (1.86-14.5)
Birth weight Case-control 148 ALL Birth weight >3999 g The results suggest that high
birth weight is associated with an
increased risk of infant leukemia.
Koifman et al.,
2008 [30]53 AML OR 1.59 (0.79-3.17)
 ALL OR 2.28 (1.08-4.75)
 MLL+ OR 2.68 (0.99-7.15)
Birth characteristics
and maternal
reproductive history
Case-control 149 ALL Birth weight ≥4,000 g Maternal history of fetal loss and
other birth characteristics were
not related to infant leukemia.
Spector et al.,
2007 [31]91 AML OR 1.09 (0.67-1.79)
 Gestational age <37 weeks
 OR 0.74 (0.32-1.70)
 Birth order 2nd
 OR 0.60 (0.40-0.91)
 Maternal age ≥35 years
 OR 0.75 (0.46-1.23)
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Variables studied Study design Cases analyzed OR (95% CI) Conclusions Author and year
 Prior fetal loss Any
 OR 1.04 (0.70-1.55)
 Pre-pregnancy BMI 25-29.9
 OR 1.61 (1.04-2.48)
 Weight gain during pregnancy
(kg)>18.14
 OR 1.50 (0.84-2.68)
Maternal anemia Case-control 178 Acute leukemia Anemia during pregnancy (<11 g dl-1) The authors did not find evi‐
dence for an increased risk of
leukemia in the offspring of
mothers with hemoglobin <11 g
dl-1 during pregnancy.
Peters et al., 2006
[32]OR 0.93 (0.57-1.53)
ALL OR 1.14 (0.65-2.01)
AML OR 0.67 (0.32-1.37)
ALL/MLL+ OR 0.98 (0.50-1.91)
AML/MLL- OR 0.57 (0.16-2.07)
Maternal illicit drugs,
pain medication, vita‐
mins/iron supplement,
folic acid, hormones,
abortive drugs, herbal
infusions, pesticides
during pregnancy
Case-control 202 Acute leukemia TobaccoORa 0.89 (0.63-1.25) A statistically significant associa‐
tion between the maternal use
of hormones during pregnancy
and infant leukemia.
Pombo-de Oliveira
et al., 2006 [33]MarijuanaORa 0.87 (0.63-1.20)
DipyroneORa 1.45 ( 1.02-2.06)
Amoxicillin ORa 0.88 (0.63-1.25)
Folic acid ORa 1.22 (0.73-2.05)
MetronidazoleORa 1.39 (0.82-2.34), Mi‐
soprostolORa 1.23 (0.38-4.02)
Hormones ORa 8.76 (2.85-26.93)
Herbal infusions ORa 1.93 (0.49-7.58)
Pesticides ORa 2.18 (1.53-2.13)
Hormones intake:
Preconception
OR 2.26 (1.21-4.21); MLL+ OR 3.34
(1.51-7.36)
1st trimester OR 11.35 (3.20-40.20);
MLL+ OR 10.57 (2.33-47.91)
2nd trimester OR 4.49 (1.07-18.87); MLL
+ OR 2.62 (0.15-17.56)
3rd trimester OR 2.32 (0.60-8.98); MLL+
1.02 (0.10-9.93)
Maternal diet (DNA
topoisomerase II
Case-control 149 ALL DNAt2 inhibitor with MLL+ Maternal consumption of vege‐
tables and fruits were associated
Spector et al.,
2005 [34]91 AML Quartile 4 OR 0.7 (0.4-1.5)
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Variables studied Study design Cases analyzed OR (95% CI) Conclusions Author and year
inhibitor)  with a decreased risk of infant
leukemia, particularly MLL+.
DNAt2 inhibitors increase the risk
of AML (MLL+).
ALL OR 0.5 (0.2-1.1)
 AML OR 3.2 (0.9-11.9)
 Vegetable and fruits plus index
 Quartile 4 OR 0.6 (0.3-1.1)
 ALL OR 0.5 (0.2-0.9)
 AML OR 1.1 (0.4-2.9)
Maternal smoking, al‐
cohol, DNA damaging
drugs, herbal medi‐
cines, pesticides, Di‐
pyrone,
insecticides
Case-control 49 ALL (19 MLL+) Smoking The data suggest that specific
chemical exposures of the fetus
during pregnancy may cause MLL
gene fusions.
Alexander et al.,
2001 [35]74 AML (29 MLL+) ALL OR 1.59 (0.82-3.07); AML OR 1.33
(0.63-2.80); MLL+ OR 0.98 (0.46-2.09)
13 Other (2 MLL+) Alcohol
 ALL OR 0.63 (0.25-1.60); AML OR 1.92
(0.90-4.10); MLL+ OR 0.74 (0.29-1.90)
 DNA Damaging drugs
 ALL OR 1.78 (0.95-3.34); AML OR 2.28
(1.10-4.71); MLL+ OR 2.31 (1.06-5.06)
 Herbal medicines
 ALL OR 4.45 (2.06-9.63); AML OR 2.09
(0.89-4.92); MLL+ OR 3.00 (1.38-6.54)
 Maternal Pesticide
 ALL OR 2.53 (0.71-8.97); AML OR
5.08(1.84-14.04); MLL+ OR 4.96
(1.71-14.43)
 Dipyrone
 ALL OR 3.13 (1.02-9.57); AML OR 3.01
(0.93-9.79); MLL+ OR 5.84 (2.09-16.30)
 Insecticides
 ALL OR 4.30 (0.66-28.08); AML OR 7.82
(1.73-35.39); MLL+ OR 9.68 (2.11-44.40)
Table 1. Risk factors for infant leukemia studied in the last 12 years.
3. Clinical characteristics
Infants with leukemia possess different molecular genetics features, immunophenotypes and
cytogenetic characteristics with respect to older children. Infants with ALL have a very high
leukocyte count (hyperleukocytosis); the median of leukocyte count in infants with ALL was
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recorded as 100 x 109 L. Infants with ALL also often exhibit hepatosplenomegaly, widened
mediastinum, and compromise of the central nervous system (CNS) in approximately 15% of
cases. In addition, 13% of male infants exhibit infiltrated testes [16,17]. The ratio ALL/AML in
infants is approximately 1.5-2.0, and the M4 or M5 morphology predominates in infants
diagnosed with AML [5,18,19].
A significant proportion of infants diagnosed with ALL are characterized by a very immature
precursor B-lineage ALL – pro B CD-10. The mature B-lineage ALL is very rare and only 4%
of cases are of T-lineage [13]. The leukemic cells of infants with ALL express myeloid antigens,
which may indicate that this type of leukemia is generated in immature precursor cells that
have no lymphoid differentiation [17]. Unlike older children diagnosed with ALL, with a 5-
year survival rate of 80%, infants with leukemia have a very poor 5-year survival rate of 50%
or less. The 5-year survival rate for infants with AML is 40%, similar to that reported in older
children [20-22].
4. Genetic characteristics in infants
Both ALL and AML in infants are frequently associated with abnormalities (genetic rear‐
rangements) involving the Mixed Lineage Leukemia (MLL) gene, also called Htrx, ALL-1 or
HRX, which is located on chromosome 11 band q23 [36-38]. This gene is fused promiscuously
with different pairs of chromosomes; up to 70 partners have been reported in human leukemia
[39]. The most common fusion partners include chromosome 4, reported in 50% of cases;
chromosome 11, with a frequency of 20%; and chromosome 9, present in 10% of cases. Fusions
of chromosome 9 are presented in older infants, unlike fusions of chromosomes 4 or 11 [40,41].
The ENL chromosome has also been found fused with MLL, although at a lower frequency
[38]. Infants with the MLL gene have a very poor prognosis compared with older children with
the disease [13,42,43].
MLL translocations are present in 75-85% of ALL infants less than 1 year and in 60% of infant
AML casesMLL translocations are found in older children and are reported in 5% of cases of
childhood AL and 85% of leukemias secondary to treatment with topoisomerase II inhibitors,
which are usually AMLs [37,42,44,45]. This last frequency is very important because it has
implications for the etiology of leukemia in infants.
5. Structure of the MLL gene
The MLL gene is located on chromosome 11q23 just after the repressor domain. The MLL gene
is 90 kb, consists of 38 exons, and produces a 12-kb mRNA that encodes a 430-kDa protein of
3969 amino acids in a complex structure. This protein is widely expressed in the developing
embryo, where it functions as a regulator of nuclear transcription. In adult tissues, the protein
is only minimally expressed [38,41,46,47].
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The MLL protein is normally cleaved in the cytoplasm by caspasa 1 at amino acids 2666
(cleavable site 1 or CS1) and 2718 (cleavable site 2 or CS2), generating two subunits: the 300-
kDa MLL-N and the 180-kDa MLL-C. MLL functions to acetylate, deacetylate and methylate
the histones of nucleosomes [40,46]. The mature protein contains a 8.3-kb breakpoint cluster
region between exons 5 and 11, and multiple protein domains have been identified: AT hooks,
a DNA methyltransferase domain (transcriptional repression domain, TRD), a Plant homology
domain (PHD), a transcription activator domain (TA) and Su (var) 3-9 enhancer of zest
trithorax (SET) domain [38,47,48].
MLL gene alterations include deletions, duplications, inversions and reciprocal translocations.
In reciprocal translocations, the fusion proteins are generated by interactions with the C-
termini of other genes to replace the transcriptional repression and nuclear signaling domains
located at the N-terminus of the MLL protein [49,50].
These fusion proteins have been postulated to be involved in leukemogenesis by increasing
the expression of the HOXA9 gene during embryo development. The HOXA9 gene encodes a
transcription factor, and the increased expression of this gene could represent a critical
mechanism for MLL-related leukemia [46,49,51]. Another mechanism by which these fusion
proteins promote leukemia is to increase the expression of FLT3 tyrosine kinase [41,52].
6. Prenatal origin
Numerous molecular biology studies have been conducted in twins with blood samples
collected at  birth from newborns (Guthrie cards) and with blood samples from the um‐
bilical cord to detect inborn metabolic problems and other problems that could occur in
newborns. Neonatal blood samples are stored, and thereafter the samples of a child with
a diagnosis  of  leukemia are  examined to  understand the  patient’s  genetic  abnormalities
at  birth.  These  abnormalities  are  compared with  those  reported  in  the  diagnosis  of  the
patient. In a large proportion of neonatal blood samples, studies have concluded that the
leukemia likely started in  utero  during fetal  hematopoiesis,  although this  is  not  true for
all chromosomal abnormalities [14,53,54].
Monozygotic and dizygotic twins have also been studied to determine the heritable fraction
of childhood leukemia. More than 50% of twins share a placenta (monozygotic), which allows
blood exchange. In these cases, it is likely that if one of the twins had a leukemic clone, it may
have an intraplacentarian metastasis through which the clone could be transmitted to the other
twin [37,53]. This hypothesis has been demonstrated through studies in twins with leukemia
using translocation markers for unique genetic breakpoints, especially in TEL-AML1 and MLL
rearrangements [14,53-55].
In twin infants with a diagnosis of leukemia, the concordance rate was approximately 100%
among those twins who shared the placenta [53]. An explanation for this is that the MLL gene
is sufficient to cause leukemia, which could happen if the protein has an overall effect on the
structure of chromatin or on the stability of gene expression [37,56]. It is likely that the effect
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of the MLL gene in DNA repair or cell cycle regulation facilitates additional genetic changes
caused by continuous exposure to genotoxic chemicals in utero [14]. However, some authors
have noted that the MLL gene is not sufficient to generate leukemogenesis and that additional
secondary genetic events are necessary in the development of the disease [57,58]. More so when
it has reported the presence of this rearrangement in children over 1 year of age which raises
the possibility that the relation of this rearrangement to the development of ALL is similar to
that of the TEL-AML1 rearrangement; that is, it is an essential cause, but it is indispensable
that another environmental factor be involved in order for children with this rearrangement
(acquired at birth or not) to develop the disease [59].
Unlike infant leukemias, acute leukemias in older children exhibit a concordance rate between
identical twins who share the same placenta of only 10%. This finding, together with transgenic
models, indicates that post-natal events are necessary to produce sufficient genetic changes to
develop leukemia. This finding explains why leukemia in infants is a different entity than that
of older children, and attention must be paid to transplacental exposure in utero during
embryonic development and fetal hematopoiesis [37,60].
7. Enzyme DNA topoisomerase II
The  function  of  the  enzyme  DNA  topoisomerase  II  (DNAt2)  is  to  relax  the  DNA
strands  that  are  tightened  and  knotted  during  cell  replication  [61].  DNAt2  generates  a
break  in  the  double  strands  of  DNA  that  are  then  re-sealed,  causing  a  relaxation  of
the  DNA.  Some drugs  used  in  the  treatment  of  leukemia,  such  as  the  epidofilotoxinas
and  anthracyclines,  have  apoptotic  effects  by  inhibiting  DNAt2.  These  drugs  interfere
with  the  normal  function  of  DNAt2  by  stabilizing  the  break-cleavable  complex,  which
is  the  DNAt2  enzyme  complex  responsible  for  breaking  the  double-stranded  DNA,
slowing the ligation of  the strands and leaving free  the single-stranded DNA ends that
can  lead  to  chromosomal  abnormalities.  These  chromosomal  abnormalities  have  been
observed in  leukemias  secondary to  the  treatment  of  epidofilotoxins  and anthracyclines
in  children  and  adults  [62,63],  and  patients  treated  with  these  drugs  have  a  greater
likelihood  of  developing  secondary  AML  with  MLL  translocations  [64].  Several  chemi‐
cal  compounds  are  able  to  inhibit  DNAt2,  including  chemotherapeutic  drugs  contain‐
ing  quinone  substances  [65,66].  The  enzyme  NAD(P)h:quinone  oxidoreductase  1
(NQO1)  is  involved in  the  metabolism of  chemicals  that  inhibit  DNAt2.  The  functional
polymorphism  C609T  reduces  the  activity  of  NQO1  and  exhibits  a  phenotypic  dose-
gene  effect  [67,68].  Several  studies  have  assessed  the  associated  risk  of  possessing  the
variant  allele  T  at  locus  NQO1  C609T  in  patients  with  childhood  AL  and  MLL  rear‐
rangement.  The  results  are  mixed;  only  some  studies  observed  an  increased  risk  with
NQO1 C609T in infants  with leukemia and MLL [66,69,70].
However, there are other sources of exposure to DNAt2 inhibitors that may increase the risk
of acute leukemia in infants [42]. These DNAt2 inhibitors are found in some drugs, substances
derived from benzene and naturally in some foods that contain flavonoids [71].
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8. Therapy-related secondary leukemias
The  growing  use  of  intensive  therapies  in  the  treatment  of  patients  with  cancer  has
caused an increase in the incidence of secondary neoplasms. The complexity of anti-can‐
cer  treatments  makes  it  difficult  to  know  what  agents  are  more  leucemogenous  and
which act  more quickly in  the leukemic transformation of  the hematopoiesis  progenitor
cells.  The term secondary leukemia is  usually employed to indicate both forms of AML
evolving from previous myelodysplasia and forms of acute leukemia developing after ex‐
posure  to  environmental  or  therapeutic  toxins  or  radiation  (therapy-related).  Secondary
leukemias account for 10-30% of all AML. The majority of secondary leukemias resulting
from the use of cytotoxic drugs can be divided into two well defined groups depending
on whether the patient has received: 1) alkylating agents or 2) drugs binding to the en‐
zyme DNA-topoisomerase II.
Alkylating  agents  related  leukemias  are  very  similar  to  post  myelodysplasia  leukemias
being characterized frequently by a preleukemic phase, trilineage dysplasia, frequent cy‐
togenetic abnormalities involving chromosomes 5 and 7 and a poor prognosis. Secondary
leukemias related to therapy with topoisomerase II inhibitors are not preceded by a pre‐
leukemic  phase  and  show  frequently  balanced  translocations  involving  chromosome
11q23.  Among therapy-related  leukemias,  AML is  generally  a  second neoplasm,  thus  a
predisposition to malignancy, independently from previous chemotherapy, cannot be ex‐
cluded. It  has been mentioned that the incidence of  secondary leukemias increases with
age [72]  and leukemic cells  predominantly exhibit  a  monocytic  or  myelomonocytic  phe‐
notype  and balanced chromosomal  translocations  including 11q23  and 21q22  rearrange‐
ments  or  abnormalities  such  as  t(15;17)(q22;q12)  and  inv(16)(p13q22).  A  history  of
previous  treatment  with  topoisomerase-II-inhibitors  is  common  in  these  individuals.
However,  as  many patients  have  received multiple  lines  of  treatment  including  several
classes of  chemotherapy compounds,  both structural  and balanced chromosomal aberra‐
tions  are  frequently  observed  in  the  leukaemic  clone.  The  World  Health  Organization
(WHO) has therefore abandoned its former classification into alkylating agent or topoiso‐
merase-II-inhibitor  associated  therapy-related  disease.  As  a  conservative  estimate,  about
10% of cases of AML and myelodysplastic syndrome (MDS) are therapy related [73].
Alkylating agents
Alkylating agents were the first chemotherapeutic compounds to be associated with leukaemia
development after successful treatment of solid and haematological cancers [74-78]. They
comprise a large group of anti-cancer drugs with clinical application across almost all cancer
types. Alkylating agents induce DNA damage by transferring alkyl groups – such as -CH3 or
-CH2-CH3 – to oxygen or nitrogen atoms of DNA bases, resulting in highly mutagenic DNA
base lesions, such as O6-methylguanine and N3-methylcytosine [79-82].
Drugs binding to the enzyme DNA-topoisomerase II (topoisomerase inhibitors)
While  alkylating agents  associated with  therapy-related myeloid neoplasms (t-MNs)  are
characterized by a complex karyotype often featuring partial or complete loss of chromo‐
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somes 5 and/or 7, exposure to topoisomerase inhibitors leads to the development of leu‐
kaemias  with  balanced  translocations  involving  MLL  at  11q23,  RUNX1  at  21q22  and
RARA at  17q21 [83-85].  MLL fusion genes are also MLL fusion genes are also common
in secondary acute myeloid leukemia (usually French-American-British (FAB) M4/M5) as‐
sociated with prior therapeutic exposure to topoisomerase-II  inhibiting anthracyclines or
epidophyllotoxins [62].  These observations have prompted speculation on possible expo‐
sure  to  topoisomerase-II  inhibiting substances  during pregnancy that  might  give  rise  to
MLL fusions during fetal hematopoiesis [86].
DNA topoisomerases are critical enzymes responsible for unknotting and relaxing supercoiled
DNA, thus allowing DNA replication to occur. To relax supercoiled DNA, topoisomerases
bind covalently to the DNA strand and create transient single (type I topoisomerases) and
DSBs (type II topoisomerases). These DNA strand breaks are readily religated after topoiso‐
merases are released from the DNA [87]. As these ubiquitous enzymes are essential to cell
survival, DNA topoisomerases have become a valuable target for several cytostatic drugs, such
as epipodophyllotoxins and anthracyclines. Topoisomerase inhibitors block the release of
topoisomerases from cleaved DNA, preventing religation of the DNA strands [88]. Thus,
topoisomerase inhibitors lead to the generation of permanent DNA DSBs that trigger DSB-
induced apoptosis. However, persistent DNA DSBs are also highly mutagenic and can result
in chromosomal deletions, insertions, inversions and translocations, all of which are charac‐
teristic of the leukaemic cell clone in t-MNs. The exact molecular effects of these inhibitors on
the acquisition of chromosomal aberrations and the development of this t-MN subtype have
recently been reviewed in detail [89].
Dexrazoxane – a bisdioxopiperazine iron chelator used to reduce cardiopulmonary toxici‐
ty in patients treated with anthracyclines – also interferes with topoisomerase II in its di‐
merized state by bridging and stabilizing the ATPase region. In a randomized phase III
study in paediatric patients treated with chemo- and radiotherapy for Hodgkin´s disease,
dexrazoxane was associated with a cumulative incidence of MDS/AML of 2.5% - 1.0% as
compared  with  0.85%  -  0.6%  for  the  non-dexrazoxane  group  (P  =  0.16).  This  trend  to‐
wards an increased risk of secondary neoplasms associated with dexrazoxane was subse‐
quently  confirmed  in  patients  with  childhood  acute  lymphoblastic  leukaemia  [90].  In
children  cured  of  ALL,  the  risk  of  a  therapy-related  acute  myeloid  leukaemia  (t-AML)
has been evaluated in different series to be between 3.8% at 6 years and 5.9% at 4 years
[64,91-96]. The risk of secondary acute myeloid leukemia (sAML) was higher among ALL
children  who  received  a  high  cumulative  dose  of  epipodophyllotoxins  (>4,000  mg/m2)
and prolonged epipodophyllotoxin therapy in weekly or twice-weekly doses. In adults a
GIMEMA study demonstrated a  low incidence  of  t-AML,  which could be  explained by
the  lower  doses  of  epipodophyllotoxins  administered  in  the  various  therapeutic  ap‐
proaches used for the treatment of adult ALL [96].
MLL gene has been involved in secondary leukemias treatment, mainly of the type AML in
patients treated with inhibitors of topoisomerase II as a primary cancer treatment. It has been
postulated the presence of similar mechanisms for Leukemia in infants whose mothers had
exposure to native II topoisomerases [97].
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9. Diet and infant leukemia
Studies on environmental risk factors related to AL with MLL rearrangements have focused
on maternal diet effects on in utero exposure. Dietary compounds exists that can inhibit the
function of DNAt2, thereby posing a potential leukemogenesis threat in infants [43,64]. DNAt2
is critical in cellular processes such as replication, where transiently breaks down and subse‐
quently seals the DNA strand [37]. DNAt2 is able to rapidly increase its activity during cell
division [98]. Diet is a natural source of DNAt2 inhibitors, including flavonoids [71,99].
Flavonoids are a very large group of Polyphenolic compounds found in foods of plant origin.
Polyphenols are involved in the development and reproduction of plants, and they provide
resistance against pathogens, plagues and protect crops from diseases that inhibit the germi‐
nation of their seeds [100]. Flavonoids are divided into 6 subgroups: flavones, flavanols,
flavanones, catechins, anthocyanidins and isoflavones [71] (see table 2); in the last decade, more
than 5000 subclasses have been identified [101,102]. Importantly, several biological effects have
been observed in in vitro studies of flavonoids, including its antioxidant activity, modulation
of enzyme activity, inhibition cell proliferation and use as antibiotics, anti-allergy, anti-
diarrhea, anti-ulcer and anti-inflammatory agents [103-106].
The properties attributed to flavonoids have prompted increased interest in alternative
medicine and herbal remedies. Numerous foods, beverages and supplements exist on the
market that contains high levels of flavonoids. Therefore, it is likely that the amount of
flavonoids in the typical diet is presently increasing [102].
The study the consumption of DNAt2 inhibitors during pregnancy in women who have
children who develop leukemia is founded on the idea that foods containing natural DNAt2
inhibitors cause damage to DNA, much in the same way as the epidofilotoxinas. There have
been several bioavailability studies on flavonoids that have demonstrated that there are
differences in their absorption, depending on the source of food. The accumulation of these
compounds in blood has been measured [107]. Some studies in animals and in vitro have
demonstrated that flavonoid DNAt2 inhibitors are capable of crossing the placenta and
damaging DNA [108,109]. One study reported the flavonoids can cause a break in the MLL
gene in hematopoietic progenitor cells, which was reversible when the exposure was removed.
The site of disruption caused by the flavonoids was co-localized with the same site associated
with the epidofilotoxinas [37,60,99]. All of these findings provide evidence for epidemiological
studies in the pursuit of this association with leukemia in infants.
Studies of maternal diets during pregnancy and their association with childhood AL have been
led by Ross JA. [110], who through a case-control study in infants and a questionnaire for
maternal exposure to dietary DNAt2 inhibitors and drugs in pregnancy observed a statistically
significant association between AML and the medium and high consumption of DNAt2
inhibitors (OR 9.8; 95% confidence interval [CI] 1.1-84.8; OR 10.2; 95% CI 1.1-96.4). However,
this study observed no association with ALL. Ross JA intends to continue studying infants
with AL and stresses the importance of incorporating molecular markers that could provide
more information.
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Later, Jensen CD et al. [111] studied maternal diet and its association with childhood ALL
through a food frequency questionnaire, observing a protective effect with the consumption
of vegetables, protein and fruits (OR 0.53; 95% CI 0.33-0.85; OR 0.40; 95% CI 0.18-0.90; OR 0.71;
95% CI 0.49-1.04, respectively). In 2005s Spector et al. [34] published the results of a case-control
study in infants in which they proposed that exposure to high levels of DNAt2 inhibitors in
the diet was associated with the risk of MLL+ leukemia in infants. The authors observed a non-
significant association between MLL+ AML but a trend among the second and fourth quartiles
of DNAt2 inhibitor consumption (OR 1.9; 95% CI 0.5-7.0; OR 2.1; 95% CI 0.6-7.7; OR 3.2; 95%
CI 0.9-11.9). A non-significant inverse association was observed with MLL+ ALL. Another
study conducted by Petridou et al. [112] in children ≤4 years old diagnosed with ALL asked
about the mothers’ diets during pregnancy and found that the consumption of fruits (OR 0.72;
95% CI 0.57-0.91), vegetables (OR 0.76; 95% CI 0.60-09) and fish/seafood (OR 0.72; 95% CI
0.59-0.89) decreased the risk for ALL. However, the consumption of sugar/honey and meat/
derivatives increased the risk for ALL (OR 1.32; 95% CI 1.05-1.67; OR 1.25; 95% CI 1.00-1.57,
respectively). The most recent study on maternal diet and childhood ALL was undertaken by
Kwan ML et al., [113] who applied a food-frequency questionnaire about food consumed 1
year before pregnancy. The results of their study indicate that the risk for ALL was inversely
associated with maternal consumption of vegetables (OR 0.65; 95% CI 0.50-0.84), sources of
protein (OR 0.55; 95% CI 0.32-0.96), fruits (OR 0.81; 95% CI 0.65-1.00) and legume food groups
(OR 0.75; 95% CI 0.59-0.95).
Flavones
(Apigenin,
luteolin,
diosmetin)
Flavonols
(Quercetin,
myrecetin,
kaempferol)
Flavanones
(Naringenin,
hesperidin)
Catechins or
Flavanols
(Epicatechin,
gallocatechin)
Anthocyanidins
(Pelargonidin,
malvidin, cyanidin)
Isoflavones
(Genistein,
daidzein)
Parsley Onions Citrus foods Tea Cherries Soya beans
Thyme Kale Prunes Apples Grapes Legumes
Celery Broccoli Cocoa
Sweet red Apples
pepper Cherries
Fennel
Sorrel
Berries
Tea
Table 2. Major subgroups of flavonoids and food sources.
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Thus far, epidemiological studies have identified the protective effect of fruits and vegetables
consumption during pregnancy against infantile ALL. These results are not observed in AML
with the exception of the studies of Ross et al., in which the authors identified a positive
association between the high intake of DNAt2 inhibitors in foods and AML/MLL+ in infants.
These results confirm that AL in children is composed of different subgroups with different
disease etiologies [37,42].
The most recent epidemiological study in infants is the one published by the group of Ross et
al., [114] with a significant number of cases (374). In this study, the authors describe some of
the demographic factors and the MLL gene status in infants with leukemia. They generally
reported a higher frequency of females (50.8%), and the most common ethnic group was
Caucasian (70%), followed by Hispanics (27.8%). The most frequent age of diagnosis was 4-6
months (27.8%), and 51.5% of cases were MLL+, 33.0% were MLL-, and 15.6% were undeter‐
mined. The chromosome most frequently found fused to the MLL gene was chromosome 4 [t
(4; 11)]. Interestingly, the black ethnic group had a lower risk of MLL+ leukemia (OR 0.27; 95%
CI 0.11-0.70), and a protective effect was observed in infants 10-12 months old (OR 0.39; 95%
CI 0.21-0.73). Cases of ALL and t(9;11) were diagnosed at older ages than cases with t(4;11) or
other translocations (P = 0.01). These findings provide important information of the biology of
the disease. Undoubtedly, this study necessitates future publications to report socio-economic
data, exposure to DNAt2 inhibitors and other maternal risk factors during pregnancy and their
association with leukemia in infants.
Another study is currently being conducted by our research group in Mexico City. This study
emerged because Mexico City has a high incidence rate of acute leukemia in infants. In
addition, a previous study observed that the frequency of MLL/AF4 rearrangements in patients
diagnosed with childhood leukemia was high [59]. This is an epidemiological case-control
study in infants; the objectives are to identify the relationship between in utero exposure to
environmental factors inhibiting DNAt2 that are present in the maternal diet during pregnan‐
cy, including drugs and benzene derivatives. Biological samples of patients are being analyzed
to detect the MLL/AF4 gene rearrangement in infants. In addition, we will know the frequen‐
cies of exposure to environmental factors that inhibit DNAt2 in the mothers of infants with
MLL+ AL. Nine hospitals that belong to the most important public health institutions in our
country are participating in this study. These hospitals diagnose and treat 97.5% of all leukemia
cases in Mexico City [7]. The results obtained from this study will be very relevant to one of
the cities with the highest incidence rates for childhood AL.
10. Future directions
Due to the findings reported thus far, the authors have recommended carrying out studies in
infants that are focused on different biological strata like female/male rations because hormo‐
nal differences could indicate an important predisposition to the presence of MLL+ rearrange‐
ment. Another suggestion is to study different ethnic groups, where the genetic involvement
can provide substantial information about this cohort [112]. For future studies, one must
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consider the importance of a big sample size, questionnaires validated and, when possible to
incorporate biological or environmental samples that enhance the exposure information, such
as pre-diagnostic biological samples. In addition to considering collaborative studies between
epidemiologists, clinicians, biologists, and others will enrich the results of these studies.
11. Conclusion
There is sufficient evidence to indicate that acute leukemia in infants is initiated in utero with
MLL rearrangements. Epidemiological studies have demonstrated that flavonoids and some
benzene derivatives present in the maternal diet during pregnancy can act as inhibitors of
DNAt2 and are associated with the development of AML in infants with MLL+. This associa‐
tion has not been observed for ALL in infants, although an inverse association with the
consumption of vegetables and fruits has been reported for ALL. Is a priority to identify
environmental or other types of factors that could be contributing to the greater presence of
this type of rearrangement during pregnancy and their association with leukemia in infants.
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